6. Sinovac Biotech ( SVA), a holding company, is an integrated China-based biopharmaceutical company focusing on vaccines against infectious diseases. Sinovac will announce third-quarter results Nov. 14.

Net income for the third quarter of 2011 is estimated at $1.36 million compared to a net loss of $300,000 in the year ago quarter, as per analysts polled by Bloomberg. Sales are forecast at $12.1 million, up 27% from $9.55 million in the third quarter of 2010. Gross margin for the quarter is seen increasing to 73% from 68.26% in the year-earlier quarter. Operating profit is seen swinging to positive $2.23 million from a $740,000 operating loss in the year-ago quarter.

Of the three analysts covering the stock, 33% recommend a buy and the rest suggest a hold. There are no sell ratings on the stock. Analysts polled by Bloomberg expect the stock to gain an average 78.9% to $3.90 from current levels over the next 12 months.

If you liked this article you might like

InterOil Pricing Period Likely Underway as Exxon Vote Looms

Jim Cramer ExxonMobil's Bid for InterOil Is 'Anything but Conservative'

Exxon Mobil Gains Upper Hand in InterOil Bidding

5 Things You Must Know Before the Market Opens Monday

ExxonMobil Holds the Cards To Fold Oil Search's Bid for InterOil